{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:36:00Z","timestamp":1785440160006,"version":"3.56.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jpba.2020.113768","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T16:15:54Z","timestamp":1605888954000},"page":"113768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway"],"prefix":"10.1016","volume":"194","author":[{"given":"Lovekesh","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Naved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Grover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debaraj","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113768_bib0005","first-page":"37","article-title":"Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia","volume":"8","author":"Chavez","year":"2013","journal-title":"Core Evid."},{"key":"10.1016\/j.jpba.2020.113768_bib0010","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jpba.2020.113768_bib0015","first-page":"420","article-title":"Ibrutinib: implications for use in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia","volume":"6","author":"McNally","year":"2015","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.jpba.2020.113768_bib0020","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor\u2013microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2020.113768_bib0025","first-page":"3286","article-title":"Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.jpba.2020.113768_bib0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2020.113768_bib0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2020.113768_bib0040","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.3390\/ijms21114154","article-title":"Ibrutinib in gynecological malignancies and breast cancer: a systematic review","volume":"21","author":"Metzler","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2020.113768_bib0045","unstructured":"Q3A (R2) ICH Impurities in New Drug Substances International Conference on Harmonisation (ICH), Geneva, Switzerland, 2020."},{"key":"10.1016\/j.jpba.2020.113768_bib0050","unstructured":"Q3B (R2) ICH Impurities in New Drug Products International Conference on Harmonisation (ICH), Geneva, Switzerland, 2020."},{"key":"10.1016\/j.jpba.2020.113768_bib0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpba.2019.04.010","article-title":"Degradation studies of Ibrutinib under stress conditions: characterization and structural elucidation of novel degradants","volume":"172","author":"Vajjha","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113768_bib0060","first-page":"1434","article-title":"A quality by design approach for development of simple and robust reversed phase stability indicating HPLC method for estimation of ibrutinib and its impurities","volume":"12","author":"Prasad","year":"2019","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2020.113768_bib0065","article-title":"Determination of potential genotoxic impurity hydrazine hydrate in ibrutinib by RP-liquid chromatography","author":"Gopireddy","year":"2020","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.jpba.2020.113768_bib0070","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/22297928.2019.1673814","article-title":"Development and validation of a stability-indicating method for ibrutinib: identification and separation of degradation products, known and genotoxic impurities using RP-HPLC\/PDA and QDa mass detectors","volume":"10","author":"Konduru","year":"2020","journal-title":"Anal. Chem. Lett."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852031654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170852031654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:07:31Z","timestamp":1760000851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170852031654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":14,"alternative-id":["S073170852031654X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113768","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LC and LC\u2013MS\/MS studies for identification and characterization of new degradation products of ibrutinib and elucidation of their degradation pathway","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113768"}}